Recombinant human erythropoietin made in China in anemic patients with chronic renal failure: results of a clinic trial

A randomized controlled clinical trial of recombinant human erythropoietin （rHuEPO） made in China was evaluated in 25 pairs and 24 open cases of anemia resulted from chronic renal failure. The rHuEPO of EPOGEN and RECORMON were served as standard control drugs. The results showed that the total 93.9% effective rate of rHuEPO was achived in treatment of anemia due to chronic renal failure, and there were no significant diffrences between the rHuEPO made in China and EPOGEN and RECORMON. The side effects of rHuEPO were the clotting of dialysers（4.0%） and thrombosis of arteriovenous fistulae（8.5%）,but there was no significant difference compared with the control group. There were no hepatic or orther toxic effects found.